Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

With a trading volume of 7,459,075, the price of TEM is down by -4.37%, reaching $59.29. Current RSI values indicate that the stock is is currently neutral between overbought and oversold. Next ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA ...

Read about Tempus AI Inc Class A common stock (TEM:XNAS) stock and today's latest news and financial updates.

Check out our TEM stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Former House Speaker Nancy Pelosi said back in 2022 the Senate would soon vote on a bill banning members of Congress from trading individual stocks. Roughly three years later, Pelosi is no ...

We came across a bullish thesis on Vericel Corporation on R.Dennis’s Substack by OppCost. In this article, we will summarize ...

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...